.: ORİJİNAL ARAŞTIRMA
Assessment of Serum Creatinine, Cystatin C and Neutrophil Gelatinase-associated Lipocalin Levels in Rosacea: A Case-Control Study
Rozasea Hastalarında Serum Kreatinin, Sistatin C ve Nötrofil Jelatinaz İlişkili Lipokalin Düzeylerinin Değerlendirilmesi: Bir Vaka-Kontrol Çalışması
Turkiye Klinikleri J Dermatol. 2020;30(2):49-55
doi: 10.5336/dermato.2020-75109
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: Rosacea, a chronic inflammatory skin disease, is known to be associated with various systemic disorders. However, limited data are available on the association between rosacea and renal diseases. The objective of this study was to evaluate serum creatinine, cystatin C and neutrophil gelatinase-associated lipocalin (NGAL) levels in patients with rosacea without any systemic diseases. Material and Methods: A prospective, case-control study was planned to investigate the relationship between rosacea and renal involvement by evaluating serum creatinine, cystatin C and NGAL levels. Results: A total of 38 patients with rosacea and 45 healthy controls were included. Statistically significant differences in serum creatinine and cystatin C levels were noted between the patient and control groups (respectively p=0.012, p<0.001). No statistically significant difference was shown in the values of NGAL between the two groups (p=0.235). A positive correlation was noted between serum creatinine and serum cystatin C levels (r=0.434; p<0.001). The serum levels of cystatin C were positively correlated with disease duration (r=0.511, p<0.001). Conclusion: Serum creatinine and cystatin C levels may provide early detection of renal dysfunction in rosacea.
Keywords: Creatinine; cystatin C; inflammation; neutrophil gelatin ase-associated lipocalin; renal disease; rosacea
Objective: Rosacea, a chronic inflammatory skin disease, is known to be associated with various systemic disorders. However, limited data are available on the association between rosacea and renal diseases. The objective of this study was to evaluate serum creatinine, cystatin C and neutrophil gelatinase-associated lipocalin (NGAL) levels in patients with rosacea without any systemic diseases. Material and Methods: A prospective, case-control study was planned to investigate the relationship between rosacea and renal involvement by evaluating serum creatinine, cystatin C and NGAL levels. Results: A total of 38 patients with rosacea and 45 healthy controls were included. Statistically significant differences in serum creatinine and cystatin C levels were noted between the patient and control groups (respectively p=0.012, p<0.001). No statistically significant difference was shown in the values of NGAL between the two groups (p=0.235). A positive correlation was noted between serum creatinine and serum cystatin C levels (r=0.434; p<0.001). The serum levels of cystatin C were positively correlated with disease duration (r=0.511, p<0.001). Conclusion: Serum creatinine and cystatin C levels may provide early detection of renal dysfunction in rosacea.
Keywords: Creatinine; cystatin C; inflammation; neutrophil gelatin ase-associated lipocalin; renal disease; rosacea
ÖZET
Amaç: Rozasea, pek çok sistemik hastalıkla ilişkili olduğu bilinen kronik, inflamatuar bir deri hastalığıdır. Bununla birlikte rozasea ve renal hastalıklar arasındaki ilişkiyle ilgili bilgi sınırlıdır. Bu çalışmanın amacı, hiçbir sistemik hastalığı olmayan rozasea hastalarında, serum kreatinin, sistatin C ve nötrofil jelatinaz ilişkili lipokalin (NGAL) düzeylerini değerlendirmektir. Gereç ve Yöntemler: Rozasea ve renal tutulum arasındaki ilişkiyi araştırmak için serum kreatinin, sistatin C ve NGAL düzeylerini değerlendiren prospektif, vaka-kontrollü çalışma planlanmıştır. Bulgular: Toplam 38 rozasea hastası ve 45 sağlıklı kontrol çalışmaya dâhil edilmiştir. Serum kreatinin ve sistatin C düzeylerinde hasta ve kontrol grubu arasında istatistiksel olarak anlamlı fark bulunmuştur (sırasıyla p=0,012, p<0,001). NGAL değerlerinde, 2 grup arasında anlamlı bir fark bulunmamıştır (p=0,235). Serum kreatinin ve serum sistatin C düzeyleri arasında pozitif bir korelasyon izlenmiştir (r=0,434; p<0,001). Serum sistatin C düzeyleri hastalık süresiyle pozitif korelasyon göstermiştir (r=0,511, p<0,001). Sonuç: Serum kreatinin ve sistatin C düzeyleri rozasea hastalarında renal disfonksiyonun erken bir belirteci olabilir.
Anahtar Kelimeler: Kreatinin; sistatin C; inflamasyon; nötrofil jelatinaz ilişkili lipokalin; renal hastalık; rozasea
Amaç: Rozasea, pek çok sistemik hastalıkla ilişkili olduğu bilinen kronik, inflamatuar bir deri hastalığıdır. Bununla birlikte rozasea ve renal hastalıklar arasındaki ilişkiyle ilgili bilgi sınırlıdır. Bu çalışmanın amacı, hiçbir sistemik hastalığı olmayan rozasea hastalarında, serum kreatinin, sistatin C ve nötrofil jelatinaz ilişkili lipokalin (NGAL) düzeylerini değerlendirmektir. Gereç ve Yöntemler: Rozasea ve renal tutulum arasındaki ilişkiyi araştırmak için serum kreatinin, sistatin C ve NGAL düzeylerini değerlendiren prospektif, vaka-kontrollü çalışma planlanmıştır. Bulgular: Toplam 38 rozasea hastası ve 45 sağlıklı kontrol çalışmaya dâhil edilmiştir. Serum kreatinin ve sistatin C düzeylerinde hasta ve kontrol grubu arasında istatistiksel olarak anlamlı fark bulunmuştur (sırasıyla p=0,012, p<0,001). NGAL değerlerinde, 2 grup arasında anlamlı bir fark bulunmamıştır (p=0,235). Serum kreatinin ve serum sistatin C düzeyleri arasında pozitif bir korelasyon izlenmiştir (r=0,434; p<0,001). Serum sistatin C düzeyleri hastalık süresiyle pozitif korelasyon göstermiştir (r=0,511, p<0,001). Sonuç: Serum kreatinin ve sistatin C düzeyleri rozasea hastalarında renal disfonksiyonun erken bir belirteci olabilir.
Anahtar Kelimeler: Kreatinin; sistatin C; inflamasyon; nötrofil jelatinaz ilişkili lipokalin; renal hastalık; rozasea
REFERANSLAR:
- Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907-12. [Crossref] [PubMed]
- Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update. J Am Acad Dermatol. 2018;78(4):786-92. [Crossref] [PubMed]
- Chiu HY, Huang WY, Ho CH, Wang JJ, Lin SJ, Hsu YW, et al. Increased risk of chronic kidney disease in patients with rosacea: a nationwide population-based matched cohort study. PLoS One. 2017;2;12(10):e0180446. [Crossref] [PubMed] [PMC]
- George JA, Gounden V. Novel glomerular filtration markers. Adv Clin Chem. 2019;88:91-119. [Crossref] [PubMed]
- Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;2-8;365(9466):1231-8. [Crossref]
- Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol. 2006;26(3):287-92. [Crossref] [PubMed]
- Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006;6(7):1639-45. [Crossref] [PubMed]
- Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;3;148(11):810-9. [Crossref] [PubMed] [PMC]
- de la Sierra A. New American and European hypertension guidelines, reconciling the differences. Cardiol Ther. 2019;8(2):157-66. [Crossref] [PubMed] [PMC]
- Holmes AD, Spoendlin J, Chien AL, Baldwin H, Chang ALS. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018;78(1):156-66. [Crossref] [PubMed]
- Duman N, Ersoy Evans S, Atakan N. Rosacea and cardiovascular risk factors: a case control study. J Eur Acad Dermatol Venereol. 2014;28(9):1165-9. [Crossref] [PubMed]
- Hua TC, Chung PI, Chen YJ, Wu LC, Chen YD, Hwang CY, et al. Cardiovascular comorbidities in patients with rosacea: a nationwide case-control study from Taiwan. J Am Acad Dermatol. 2015;73(2):249-54. [Crossref] [PubMed]
- Shankar A, Klein R, Klein BEK. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006;1;164(3):263-71. [Crossref] [PubMed]
- Kawaguchi Y, Mine T, Kawana I, Yasuzaki H, Kokuho T, Toya Y, et al. Gastroesophageal reflux disease in chronic renal failure patients: evaluation by endoscopic examination. Tokai J Exp Clin Med. 2009;20;34(3):80-3.
- Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension. 2003;42(5):1050-65. [Crossref] [PubMed]
- Kang HT, Kim JK, Shim JY, Lee HR, Linton JA, Lee YJ, et al. Low-grade inflammation, metabolic syndrome and the risk of chronic kidney disease: the 2005 Korean National Health and Nutrition Examination Survey. J Korean Med Sci. 2012;27(6):630-5. [Crossref] [PubMed] [PMC]
- Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol. 2004;15(3):538-48. [Crossref] [PubMed]
- Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton). 2012;17(4):311-21. [Crossref] [PubMed]
- Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Invest Dermatol. 2015;135(9):2198-2208. [Crossref] [PubMed]
- Granata S, Masola V, Zoratti E, Scupoli MT, Baruzzi A, Messa M, et al. NLRP3 inflammasome activation in dialyzed chronic kidney disease patients. PLoS One. 2015;23;10(3): e0122272. [Crossref] [PubMed] [PMC]
- Lahoud Y, Hussein O, Shalabi A, Nativ O, Awad H, Khamaisi M, et al. Effects of phosphodiesterase-5 inhibitor on ischemic kidney injury during nephron sparing surgery: quantitative assessment by NGAL and KIM-1. World J Urol. 2015;33(12):2053-62. [Crossref] [PubMed]
- Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L, et al. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;19;110(16):2342-8. [Crossref] [PubMed]
- Åkerblom A, Wallentin L, Larsson A, Siegbahn A, Becker RC, Budaj A, et al. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: Results from the PLATelet inhibition and patient outcomes (PLATO) study. Clin Chem. 2013;59(9):1369-75. [Crossref] [PubMed]
- Correa S, Morrow DA, Braunwald E, Davies RY, Goodrich EL, Murphy SA, et al. Cystatin C for risk stratification in patients after an acute coronary syndrome. J Am Heart Assoc. 2018;16;7(20):e009077. [Crossref]
- Smith ER. Cystatin C- More than a filtration marker? Atherosclerosis. 2013;230(1):73-5. [Crossref] [PubMed]
- Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, et al. Association between cystatin C and inflammation in patients with essential hypertension. Clin Exp Nephrol. 2010;14(6):584-8. [Crossref] [PubMed]
- Salgado JV, Souza FL, Salgado BJ. How to understand the association between cystatin C levels and cardiovascular disease: imbalance, counterbalance, or consequence? J Cardiol. 2013;62(6):331-5. [Crossref] [PubMed]
- Magnusson M, Molvin J, Engström G, Svensson-Färbom P, Persson M, Christensson A, et al. Cystatin C and risk of diabetes and the metabolic syndrome - biomarker and genotype association analyses. PLoS One. 2016;24;11(5):e0155735. [Crossref] [PubMed] [PMC]
- Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009;55(11):1932-43. [Crossref] [PubMed]
- Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595-605. [Crossref] [PubMed]
- Janas RM, Ochocińska A, Śnitko R, Dudka D, Kierkuś J, Teisseyre M, et al. Neutrophil gelatinase-associated lipocalin in blood in children with inflammatory bowel disease. J Gastroenterol Hepatol. 2014;29(11):1883-9. [Crossref] [PubMed]
- Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L, et al. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 1996;38(3):414-20. [Crossref] [PubMed] [PMC]
- Mårtensson J, Bell M, Xu S, Bottai M, Ravn B, Venge P, et al. Association of plasma neutrophil gelatinase-associated lipocalin (NGAL) with sepsis and acute kidney dysfunction. Biomarkers. 2013;18(4):349-56. [Crossref] [PubMed]
- Budzynska A, Nowakowska-Dulawa E, Marek T, Boldys H, Nowak A, Hartleb M, et al. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin. J Physiol Pharmacol. 2013;64(1):109-14.
- Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL): modulation of MMP-9 activity by NGAL. J Biol Chem. 2001;5;276(40):37258-65. [Crossref] [PubMed]
.: İşlem Listesi